桥接整合因子1与心力衰竭的研究进展  

Research progress on bridging integrator 1 and heart failure

作　　者：李文静[1] 李树仁[2] 苑智慧 白玉豪 Li Wenjing;Li Shuren;Yuan Zhihui;Bai Yuhao(Hebei General Hospital,Hebei Medical University,Shijiazhuang 050051,China;Department of Cardiology,Hebei General Hospital,Shijiazhuang 050051,China;Graduate School,North China University of Science and Technology,Tangshan 063210,China)

机构地区：[1]河北医科大学附属河北省人民医院,石家庄050051 [2]河北省人民医院心内一科,石家庄050051 [3]华北理工大学研究生学院,唐山063210

出　　处：《中国心血管杂志》2021年第5期495-498,共4页Chinese Journal of Cardiovascular Medicine

摘　　要：心力衰竭是多种心脏疾病的终末期表现,发病率及死亡率较高。桥接整合因子1是近几年出现的一种新型生物标记物,本文就桥接整合因子1的结构、功能以及其对心力衰竭的诊断、预后评估及治疗的潜在价值等方面进行综述。Heart failure is the end-stage manifestation of a variety of heart diseases,with high morbidity and mortality.Bridging integration factor 1 is a new type of biomarker that has emerged in recent years.This article reviews the structure and function of bridging integration factor 1 and its potential value in the diagnosis,prognosis,and treatment of heart failure.

关 键 词：桥接整合因子1 心力衰竭 新型生物标记物 

分 类 号：R541.6[医药卫生—心血管疾病]